Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Excursions

Hydrolysis, isomerisation, and the arithmetic of a broken bond

Deamidation, oxidation, aggregation and hydrolysis account for nearly all of what happens to a peptide over time. Each has a characteristic residue, a characteristic condition and a characteristic detection problem.

The single most consequential fact about deamidation is that the isoaspartate product has the same molecular weight as the parent peptide, because the rearrangement moves an atom rather than adding or removing one. A laboratory confirming identity by molecular ion mass alone will report a substantially deamidated preparation as the intended compound. Separation is possible — the isomers usually resolve on a sufficiently shallow reversed-phase gradient, and specialist methods resolve them reliably — but only if the method was designed to look. A twelve-minute generic gradient does not look.

Deamidation, and the isomer with the same mass

Deamidation of asparagine proceeds through nucleophilic attack by the backbone nitrogen of the following residue on the asparagine side-chain carbonyl, forming a five-membered succinimide intermediate which then hydrolyses to a mixture of aspartate and isoaspartate, conventionally in a ratio favouring the isomer roughly three to one. Glutamine deamidates by an analogous route, far more slowly, through a six-membered intermediate.

Three factors govern the rate. Sequence is dominant: the residue immediately following the asparagine determines how readily the intermediate forms, and asparagine-glycine is the fastest motif known, with serine, histidine and alanine following. Solution pH matters, with the rate minimal in the mildly acidic region and rising steeply above neutrality as the backbone nitrogen becomes more nucleophilic. Temperature and water activity set the overall pace, which is why the solid state helps so much.

The analytical problem is that isoaspartate has the same elemental composition and therefore the same molecular mass as the parent. Identity confirmation by molecular ion alone cannot distinguish them, and a preparation that is substantially deamidated will present as the intended compound. The isomers usually separate on a sufficiently shallow reversed-phase gradient, and specific methods exist, but only a method designed for the question will find the answer.1

Oxidation, and where the oxidant came from

Methionine oxidises to the sulfoxide and, under harsher conditions, the sulfone. Tryptophan oxidises through a series of products including kynurenine derivatives. Histidine and tyrosine are susceptible under metal-catalysed conditions, and free cysteine oxidises readily to disulphide. Each of these products differs from the parent by a defined mass increment, which makes oxidation the pathway most reliably detected by mass spectrometry: the sulfoxide is sixteen mass units heavier and unmistakable.

The interesting question is usually where the oxidant came from, and the answers are mundane. Trace transition metals leached from glass, stainless steel or a stopper catalyse oxidation of several residues. Peroxides accumulate in polysorbate surfactants during storage and are a well-documented source of methionine oxidation in formulated products. Dissolved oxygen in the diluent contributes. Light drives it, particularly for tryptophan, and light exposure during handling is entirely undocumented in this trade.

Practical consequences follow that are not obvious. A formulation containing a surfactant that has itself been stored warm for a year may oxidise a peptide that would have been perfectly stable in a plain aqueous vehicle. Headspace composition matters: vials backfilled with nitrogen behave differently from vials sealed under air, and the difference is a manufacturing choice recorded nowhere on the label.2

The aggregate arrives at the column, comes apart, and is recorded as monomer.

Callum Brathwaite, Analytical Chemistry Correspondent

Aggregation, and the method that dissolves the evidence

Aggregation covers a range of species from soluble dimers to visible particles, formed by covalent routes such as disulphide scrambling or by non-covalent association of partially unfolded monomers. For peptides the process is often nucleated at an interface — the air-water interface of a shaken vial, the silicone oil layer on a siliconised stopper, the ice-water interface formed during freezing — which is why mechanical handling and freeze-thaw cycling matter as much as temperature.

The analytical difficulty is severe and specific to the trade’s chosen method. Reversed-phase chromatography runs in an acidic, partly organic mobile phase which dissociates most non-covalent aggregates before or during separation. The aggregate is loaded and the monomer is detected. Size-exclusion chromatography under non-denaturing conditions separates by hydrodynamic volume and reports high molecular weight species directly; analytical ultracentrifugation and light scattering methods characterise them further. None of these is offered as a routine service to this market.

The consequence for a reader is that the aggregate content of a research vial is, at present, an unmeasured quantity. It is not necessarily a large one — well-made lyophilised peptides are frequently very low in aggregate — but no certificate in circulation addresses it, and the purity figure that is printed instead is generated by the one method guaranteed not to see it.3

Storage and testing conditions used in a registration stability programme
Intended storageLong-term conditionIntermediateAccelerated
Room temperature25 °C / 60% RH, ≥12 months30 °C / 65% RH40 °C / 75% RH, 6 months
Room temperature, hot climatic zone30 °C / 65% RH, ≥12 monthsnot applicable40 °C / 75% RH, 6 months
Refrigerated5 °C ± 3 °C, ≥12 monthsnot applicable25 °C / 60% RH, 6 months
Frozen−20 °C ± 5 °C, ≥12 monthsnot applicablesingle-batch excursion study
Below −20 °Ccase by casenot applicablesingle-batch excursion study
Summarised from the harmonised guideline on stability testing of new drug substances and products. Frozen-storage products are not accelerated in the usual sense; the guidance substitutes a study of the effect of a short excursion above the intended condition, which is precisely the data a shipped research vial would need and does not have.

Why accelerated data extrapolates badly for peptides

The temptation with any stability programme is to run the accelerated condition, fit an Arrhenius relationship to the rate constants, and extrapolate to the intended storage temperature. For a single reaction with a temperature-independent mechanism that is sound. For peptides it frequently is not, and the reason is that different pathways have different activation energies.

Suppose a peptide degrades at five degrees principally by deamidation and at forty degrees principally by hydrolysis, with the second having a higher activation energy. Measuring total degradation at forty degrees measures mostly hydrolysis; extrapolating that rate down to five degrees predicts almost nothing about the deamidation that will actually dominate. Aggregation is worse still, because it is frequently nucleated by interfaces and mechanical stress rather than by thermal energy alone, and does not obey a simple temperature relationship at all.

The practical rule the Journal applies when reading a stability claim is to ask what condition the data was generated at and whether the degradation products were identified as well as quantified. Accelerated data that shows which products form is genuinely useful as a warning of what to watch for. Accelerated data reduced to a single percentage and extrapolated to a shelf life is a projection dressed as a measurement, and for this class of molecule it is a poor projection.

Light, and the exposure nobody records

Photostability has its own guideline, its own defined light source options and its own exposure requirement expressed in lux hours of visible light and watt hours per square metre of near ultraviolet. Products are tested in the immediate container, and where they fail, in the marketing pack, and where they fail again the label carries a protection instruction. The chemistry is real: tryptophan and tyrosine absorb in the near ultraviolet and photo-oxidise, and photolytic disulphide cleavage is well documented.

Nothing about light exposure is recorded anywhere in the research-peptide supply chain. Vials are frequently supplied in clear glass. Photographs for listings are taken under studio lighting. Parcels are opened on kitchen counters. A reconstituted vial may sit on a shelf under a window for weeks. The cumulative exposure is unknown and unknowable, and it is plausibly a larger contributor to degradation than the transit excursions that attract all the attention.

The Journal makes one narrow observation rather than a recommendation, because recommendations are not this publication’s business. Amber glass, or a secondary carton, costs a fraction of a cent per unit and removes an uncontrolled variable entirely. Several of the twenty companies we track already ship in amber vials; most do not, and the ones that do not have not, as far as we can establish, generated any data suggesting it does not matter.4

The finding the Journal least wanted and most trusts is that the transit excursions everybody worries about are probably not the largest exposure in this supply chain. A dried cake at low moisture tolerates a warm afternoon. A reconstituted vial in a refrigerator door for six weeks, with no in-use study behind the number that justified the six weeks, is a different proposition, and it attracts almost no attention at all.

References

  1. “Asparagine deamidation in peptide and protein pharmaceuticals: sequence dependence, mechanism and analytical detection.” Journal of Pharmaceutical Sciences. 2018;107(1):1–12.
  2. “Oxidative degradation of therapeutic peptides: residues at risk and formulation countermeasures.” Journal of Peptide Science. 2021;27(4):e3298.
  3. “Size-exclusion chromatography of peptide aggregates under non-denaturing conditions: method development and limitations.” Journal of Chromatography A. 2019;1601:1–13.
  4. International Council for Harmonisation. Q1B: Photostability Testing of New Drug Substances and Products. 1996.

Letters to the Editor

1 printed

Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.

Eleven days in customs, and you describe it as a structural feature rather than a scandal. Why the restraint? A shipper advertising a cold chain that demonstrably does not survive a routine examination is making a claim it cannot support.

N. Villaseñor, Guadalajara

The Journal replies

The restraint is about where the fault lies. Customs authorities are performing a lawful function and owe nobody a thermal record. The claim of end-to-end control is the thing we criticise, and we do criticise it, in the article and again in the closing. What we will not do is convert an unavoidable feature of international freight into an allegation against the shipper who could not see it either.

Related coverage